간내 담관암: 최신 개념 및 내과적 치료 = Intrahepatic Cholangiocarcinoma: Evolving Concepts and Medical Treatment

다국어 초록 (Multilingual Abstract)

Cholangiocarcinoma (bile duct cancer) is classified into intrahepatic and extrahepatic cholangiocarcinoma (perihilar and distal cholangiocarcinoma) according to the anatomical location of the lesion. The incidence of extrahepatic cholangiocarcinoma has been relatively stagnant in recent decades, but intrahepatic cholangiocarcinoma is steadily increasing worldwide, requiring attention. Various classification systems based on gross growth patterns, histological findings, and tumor-derived cells, as well as classification based on existing anatomical location, have been proposed, however, the consensus has not been established yet. Intrahepatic cholangiocarcinoma is a carcinoma with an extremely poor prognosis. Complete tumor resection is the only curative treatment. The overall survival rate for 5 years after surgery is 15% to 40%, but recurrence after surgery is observed in 2/3 patients. Therefore, determining the right stage before surgery and selecting an appropriate treatment method through a multidisciplinary approach is a very important process in determining proper treatment. Systemic therapy may be used for locally advanced biliary tract cancer or metastatic biliary tract cancer where surgery is not possible. However, the effectiveness of traditional anticancer chemotherapeutic agents is rather pessimistic, therefore treatments using molecular biological properties have recently been attempted. Finding a way to increase the number of resectable cases through early diagnosis is one of the main challenges. In addition, it is also hoped that the selection of new therapeutic targets and therapeutics will be possible as a result of advanced research on gene expression profiles and mutations in cholangiocarcinoma.
Korean J Pancreas Biliary Tract 2021;26(1):33-42

참고문헌 (Reference)

• 1 Patel T, "Worldwide trends in mortality from biliary tract malignancies" 2 : 10-, 2002
• 2 West J, "Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001" 94 : 1751-1758, 2006
• 3 Sakamoto E, "The pattern of infiltration at the proximal border of hilar bile duct carcinoma : a histologic analysis of 62 resected cases" 227 : 405-411, 1998
• 4 Lanzoni G, "The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: a new reference frame for disease and regeneration" 64 : 277-286, 2016
• 5 Shaib Y, "The epidemiology of cholangiocarcinoma" 24 : 115-125, 2004
• 6 Pignochino Y, "Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas" 10 : 631-, 2010
• 7 Kelley RK, "Systemic therapies for intrahepatic cholangiocarcinoma" 72 : 353-363, 2020
• 8 Carpino G, "Stem/progenitor cell niches involved in hepatic and biliary regeneration" 2016 : 3658013-, 2016
• 9 Sorensen HT, "Risk of liver and other types of cancer in patients with cirrhosis : a nationwide cohort study in Denmark" 28 : 921-925, 1998
• 10 Shaib YH, "Risk factors of intrahepatic cholangiocarcinoma in the United States : a case-control study" 128 : 620-626, 2005
• 11 Shaib YH, "Rising incidence of intrahepatic cholangiocarcinoma in the United States : a true increase?" 40 : 472-477, 2004
• 12 Lubner SJ, "Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer : a phase II Consortium study" 28 : 3491-3497, 2010
• 13 Kang SH, "Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma" 25 : 240-248, 2018
• 14 Javle M, "Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma" 36 : 276-282, 2018
• 15 Nakanuma Y, "Pathological classification of intrahepatic cholangiocarcinoma based on a new concept" 2 : 419-427, 2010
• 16 Rizvi S, "Pathogenesis, diagnosis, and management of cholangiocarcinoma" 145 : 1215-1229, 2013
• 17 Nehls O, "Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial" 87 : 702-704, 2002
• 18 Li JS, "Obesity and the risk of cholangiocarcinoma : a meta-analysis" 35 : 6831-6838, 2014
• 19 Sahai V, "Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma : a phase 2 clinical trial" 4 : 1707-1712, 2018
• 20 Kim H, "Morphology of intraductal papillary neoplasm of the bile ducts : radiologic-pathologic correlation" 36 : 438-446, 2011
• 21 Liau JY, "Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features" 27 : 1163-1173, 2014
• 22 Welzel TM, "Metabolic syndrome increases the risk of primary liver cancer in the United States : a study in the SEER-Medicare database" 54 : 463-471, 2011
• 23 Adeva J, "Medical treatment for cholangiocarcinoma" 39 (39): 123-142, 2019
• 24 Lamarca A, "Liver metastases of intrahepatic cholangiocarcinoma : implications for a potential new staging system" 2020
• 25 Watanapa P, "Liver fluke-associated cholangiocarcinoma" 89 : 962-970, 2002
• 26 Lee AJ, "Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates" 7 : 52-, 2018
• 27 Donato F, "Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy" 12 : 959-964, 2001
• 28 Yamasaki S, "Intrahepatic cholangiocarcinoma : macroscopic type and stage classification" 10 : 288-291, 2003
• 29 Kobayashi M, "Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis" 88 : 2471-2477, 2000
• 30 Borger DR, "IDH mutations : new genetic signatures in cholangiocarcinoma and therapeutic implications" 12 : 543-546, 2012
• 31 Komuta M, "Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes" 55 : 1876-1888, 2012
• 32 Su CH, "Hepatolithiasis associated with cholangiocarcinoma" 84 : 969-973, 1997
• 33 Wagner AD, "Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma:two parallel, multicentre phase-II trials" 101 : 1846-1852, 2009
• 34 André T, "Gemcitabine and oxaliplatin in advanced biliary tract carcinoma : a phase II study" 99 : 862-867, 2008
• 35 Okusaka T, "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan" 103 : 469-474, 2010
• 36 Saha SK, "Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise" 21 : 594-599, 2016
• 37 Konstadoulakis MM, "Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome" 143 : 366-374, 2008
• 38 Banales JM, "Expert consensus document : cholangiocarcinoma : current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)" 13 : 261-280, 2016
• 39 Kim Y, "Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis" 116 : 643-650, 2017
• 40 Khan SA, "Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma" 10 : 77-82, 2008
• 41 Bergquist A, "Epidemiology of cholangiocarcinoma" 29 : 221-232, 2015
• 42 Zhu AX, "Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study" 11 : 48-54, 2010
• 43 Mazzaferro V, "Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma" 120 : 165-171, 2019
• 44 Spolverato G, "Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma" 115 : 696-703, 2017
• 45 Borbath I, "Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma : a phase II study of the Belgian Group of Digestive Oncology" 24 : 2824-2829, 2013
• 46 Blechacz B, "Clinical diagnosis and staging of cholangiocarcinoma" 8 : 512-522, 2011
• 47 Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer" 362 : 1273-1281, 2010
• 48 Lipsett PA, "Choledochal cyst disease. A changing pattern of presentation" 220 : 644-652, 1994
• 49 Rizvi S, "Cholangiocarcinoma-evolving concepts and therapeutic strategies" 15 : 95-111, 2018
• 50 Jarnagin WR, "Cholangiocarcinoma of the extrahepatic bile ducts" 19 : 156-176, 2000
• 51 Chapman MH, "Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis : a 25-year single-centre experience" 24 : 1051-1058, 2012
• 52 DeOliveira ML, "Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution" 245 : 755-762, 2007
• 53 Khan SA, "Changing international trends in mortality rates for liver, biliary and pancreatic tumours" 37 : 806-813, 2002
• 54 Gruenberger B, "Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study" 11 : 1142-1148, 2010
• 55 Visvader JE, "Cells of origin in cancer" 469 : 314-322, 2011
• 56 Nehls O, "Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma : a prospective multicentre phase II trial" 98 : 309-315, 2008
• 57 Petrick JL, "Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis" 113 : 1494-1505, 2018
• 58 Carpino G, "Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts : an anatomical in situ study yielding evidence of maturational lineages" 220 : 186-199, 2012
• 59 Kendall T, "Anatomical, histomorphological and molecular classification of cholangiocarcinoma" 39 (39): 7-18, 2019
• 60 Edge SB, "AJCC cancer staging handbook" Springer 648-, 2010
• 61 Amin MB, "AJCC cancer staging handbook" Springer XVII-1024, 2017
• 62 Iyer RV, "A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer" 41 : 649-655, 2018